C
Chung-Han Lee
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 102
Citations - 4893
Chung-Han Lee is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Renal cell carcinoma & Medicine. The author has an hindex of 20, co-authored 68 publications receiving 2865 citations. Previous affiliations of Chung-Han Lee include Cornell University & University of Michigan.
Papers
More filters
Journal ArticleDOI
The current role for adjuvant and neoadjuvant therapy in renal cell cancer.
TL;DR: Although there is optimism for checkpoint monotherapy and combination therapy in the adjuvant or neoadjuvant setting, ongoing studies will determine clinical benefit and tolerability in this setting.
Journal ArticleDOI
Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial
Darren R. Feldman,Darren R. Feldman,Yasser Ged,Chung-Han Lee,Chung-Han Lee,Andrea Knezevic,Ana M. Molina,Ying-Bei Chen,Joshua Chaim,Devyn Taylor Coskey,Samuel Murray,Satish K. Tickoo,Victor E. Reuter,Sujata Patil,Han Xiao,Jahan Aghalar,Arlyn Apollo,Maria I. Carlo,Maria I. Carlo,Robert J. Motzer,Robert J. Motzer,Martin H. Voss,Martin H. Voss +22 more
TL;DR: A phase 2 study of everolimus plus bevacizumab across various nonclear cell renal cell carcinoma (nccRCC) histologies and observed encouraging activity among patients with papillary RCC and unclassified RCC with a major papillary component.
Journal ArticleDOI
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Chung-Han Lee,Renzo G. DiNatale,Diego Chowell,Chirag Krishna,Vladimir Makarov,Cristina Valero,Lynda Vuong,Mark Lee,Kate Weiss,Doug Hoen,Luc G. T. Morris,Ed Reznik,Samuel Murray,Ritesh Kotecha,Martin H. Voss,Maria I. Carlo,Darren R. Feldman,Pallavi Sachdev,Yusuke Adachi,Yukinori Minoshima,Junji Matsui,Yasuhiro Funahashi,Kenichi Nomoto,A. Ari Hakimi,Robert J. Motzer,Timothy A. Chan +25 more
TL;DR: In this paper, the clinical outcomes and genomic determinants of response from a phase Ib/II clinical trial on patients with advanced RCC evaluating the efficacy of lenvatinib, a multi-kinase inhibitor mainly targeting VEGFR and FGFR plus pembrolizumab, an anti-PD1 immunotherapy.
Journal ArticleDOI
Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial.
Chung-Han Lee,Robert J. Motzer,Hamid Emamekhoo,Marc R. Matrana,I. Percent,James J. Hsieh,Arif Hussain,Ulka N. Vaishampayan,Sandy T. Liu,Steven McCune,Vijay Patel,Montaser Shaheen,Johanna C. Bendell,Alice C. Fan,Benjamin A. Gartrell,Oscar B. Goodman,Petros Nikolinakos,Arash Rezazadeh Kalebasty,Yousef Zakharia,Zhentao Zhang,Hema Parmar,Lalith Akella,Keith W. Orford,Nizar M. Tannir +23 more
TL;DR: In this article , a phase 1 trial of 2L+ renal cell carcinoma (RCC) patients was conducted, where the authors evaluated the combination of telaglenastat plus everolimus (TelaE) versus PboE (PboE) in patients with advanced/metastatic RCC in the 3L+ setting.
Journal ArticleDOI
Comprehensive Genomic Analysis of Metastatic Non–Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets
Maria I. Carlo,Nabeela Khan,Ahmet Zehir,Sujata Patil,Yasser Ged,Almedina Redzematovic,Devyn Taylor Coskey,David M. Hyman,Marc Ladanyi,Ying-Bei Chen,Mark E. Robson,A. Ari Hakimi,Chung-Han Lee,Darren R. Feldman,Jianjiong Gao,Debyani Chakravarty,Robert J. Motzer,Martin H. Voss +17 more
TL;DR: Comprehensive analysis of somatic mutations, germline mutations, and MSI, interpreted via an annotated precision oncology knowledge base, identified potentially targetable alterations in 22% of patients, which merits additional investigation.